Real-world efficacy and safety of nivolumab in previously-treated metastatic renal cell carcinoma, and association between immune-related adverse events and survival: the Italian expanded access program

BACKGROUND: The Italian Renal Cell Cancer Early Access Program was an expanded access program that allowed access to nivolumab, for patients (pts) with metastatic renal cell carcinoma (mRCC) prior to regulatory approval. METHODS: Pts with previously treated advanced or mRCC were eligible to receive...

Descripción completa

Detalles Bibliográficos
Autores principales: Verzoni, Elena, Cartenì, Giacomo, Cortesi, Enrico, Giannarelli, Diana, De Giglio, Andrea, Sabbatini, Roberto, Buti, Sebastiano, Rossetti, Sabrina, Cognetti, Francesco, Rastelli, Francesca, Sobrero, Alberto, Turci, Daniele, Sternberg, Cora N., Porta, Camillo, Cappuzzo, Federico, Tortora, Giampaolo, Tassinari, Davide, Panni, Stefano, Pazzola, Antonio, Surico, Gianmarco, Raimondi, Alessandra, De Giorgi, Ugo, Procopio, Giuseppe
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6448290/
https://www.ncbi.nlm.nih.gov/pubmed/30944023
http://dx.doi.org/10.1186/s40425-019-0579-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6448290/
https://www.ncbi.nlm.nih.gov/pubmed/30944023
http://dx.doi.org/10.1186/s40425-019-0579-z

Ejemplares similares